Therapeutic Innovation

Sep 25, 2024 | academic.oup.com | Therapeutic Innovation

A majority of genetically modified mice have been produced using 129 strain-derived embryonic stem cells (ESCs). Despite ample backcrosses with other strains, these may retain characteristic for 129 passenger mutations leading to confounding phenotypes unrelated to targeted genes. Here we show that widely used Ackr1-/-129ES mice have approximately 6Mb of the 129-derived genome retained adjacently to the Ackr1 locus on chromosome 1, including several characteristic polymorphisms.

Aug 4, 2024 | clinicalleader.com | Patrick Brady |Therapeutic Innovation

By Patrick Brady, PharmD, Global Head, Therapeutic Innovation & Regulatory Science, IQVIA The integration of artificial intelligence (AI) and machine learning (ML) into drug development and lifecycle management holds immense promise for enhancing efficiency and efficacy. AI/ML usage in clinical trials has shown the potential to aid in patient recruitment, selection, stratification, and dose optimization.

Jul 15, 2024 | journals.plos.org | Trinidad Montero-Melendez |Therapeutic Innovation

Loading metrics Open Access Peer-reviewedLab Protocol Citation: Davan-Wetton CSA, Montero-Melendez T (2024) An optimised protocol for the detection of lipofuscin, a versatile and quantifiable marker of cellular senescence. PLoS ONE 19(7): e0306275.

Mar 21, 2024 | ascpt.onlinelibrary.wiley.com | Therapeutic Innovation |Brian Lee |Aarya Ramprasad |Adara Ezekwe

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? It has previously been described that variation exists in biomarkers and devices that rely on the transmission and measurement of light across the skin surface. It is also now known that many devices and biomarkers are not validated within diverse populations. We have previously demonstrated that histamine iontophoresis with laser Doppler (HILD) assessments appear to vary across racial groups. WHAT QUESTION DID THIS STUDY ADDRESS?

Dec 20, 2023 | ascpt.onlinelibrary.wiley.com | Shen Cheng |Mahmoud Al-Kofahi |J. Steven Leeder |Therapeutic Innovation

Atomoxetine (ATX) is a non-stimulant used to treat attention-deficit/hyperactivity disorder (ADHD) and systemic exposure is highly variable due to polymorphic cytochrome P450 2D6 (CYP2D6) activity. The objective of this study was to characterize the time course of ATX and metabolites (4-hydroxyatomoxetine, 4-OH; N-desmethylatomoxetine, NDA; and 2- carboxymethylatomoxetine, 2-COOH) exposure following oral ATX dosing in ADHD children to support individualized dosing.